London, 25 January 2018, Consilium Strategic Communications, a global leader in strategic healthcare communications, today joins co-sponsors J.P. Morgan, Numis, Penningtons Manches, PwC and partners MedCity, the BioIndustry Association (BIA), and One Nucleus and London Stock Exchange to host the fourth Future of Healthcare Investor Forum at London Stock Exchange.
This one-day, invitation-only event will highlight the best innovation and explore current investment trends through a series of panels and keynote presentations from leading public and private UK and international life sciences companies. The Forum will tackle issues covering innovation in areas such as life sciences business models, respiratory therapies and for the first time, digital health.
“We are very pleased to be part of the Future of Healthcare Investor Forum and to see the data released today by London Stock Exchange and the BIA showing strength in the funding environment in the UK. The Forum provides investors with an opportunity to gain real insight into the sector, current investment trends, and leading technologies.”
Chris Gardner
Partner at Consilium Strategic Communications
In association with the Forum, London Stock Exchange has today revealed statistics which show the strength of the wider UK life sciences sector:
- £2.4 billion raised in life sciences IPOs and further offerings on London Stock Exchange in 2017, up 20% compared to 2016
- £2.1 billion raised in follow on capital a six-fold increase compared with 2016
The BIA and Informa Pharma Intelligence have also today released a new report which highlights in more detail the growing maturity of the UK biotech sector. It shows that UK biotech company IPOs raised more than twice as much money in 2017 than in 2016, and that the UK has the strongest clinical and preclinical pipeline in Europe.
Key statistics from Pipeline Progressing: the UK’s global bioscience cluster in 2017:
- UK biotech company IPOs raised more than twice as much money in 2017 (£234m) than in 2016 (£105m)
- UK biotech raised more on the public markets than in venture capital as UK companies matured and progressed through the funding lifecycle with £515m raised in venture capital, £234m raised in IPOs and £452m raised in follow on funding
- The UK has the strongest pipeline in Europe across all preclinical and clinical stages, with 351 preclinical products, 43 phase I, 70 phase II and 15 phase III
- LSE’s Main Market has seen major indirect investment through vehicles that fund the biopharma sector, including Arix Bioscience (£113m) and Biopharma Credit (£606m)
- The 2017 IPO listings on Nasdaq (NuCana plc, Nightstar Therapeutics and Verona) show that the global demand for UK biotech companies is strong
The full Pipeline Progressing report can be accessed here:
